Unfortunately, in the TME, these checkpoints, such as CTLA-4, programmed death receptor–1 (PD-1), Nectin-4, and lymphocyte activation gene 3 (LAG3) on T cells, are engaged with their partner ligand on tumor cells to downregulate immune response, leading to reduced cytotoxicity. The gene discussed is CTLA4; the disease is neoplasm.